

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shaharyar Khan

Serial No.: 10/561,829

Art Unit: 1633

Filed: December 21, 2005

Examiner: Qian Janice Li

For: *MODIFIED VECTORS FOR ORGANELLE TRANSFECTION*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of twelve (12) documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, a copy of the U.S. Patent is not enclosed. A copy will be provided upon request, however.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. 1.97(c) after a first Office Action on merits. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 C.F.R. §1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-3129.

U.S. Patent

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
6,171,863	01-09-2001	Weissig, et al.	435/458

Publications

CAO, et al., "In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis," *J. Neuroscience*, 22(13): 5423-31 (2002).

DOLGILEVICH, et al., "Transduction of TAT fusion proteins into osteoclasts and osteoblasts," *Biochem. Biophys. Res. Commun.*, 299(3): 505-9 (2002).

EMBURY, et al., "Proteins linked to a protein transduction domain efficiently transduce pancreatic islets," *Diabetes*, 50(8): 1706-13 (2001).

FENTON, et al., "The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line," *J. Immunol. Methods*, 212(1): 41-8 (1998).

FORRER and JAUSSE, "High-level expression of soluble heterologous proteins in the cytoplasm of *Escherichia coli* by fusion to the bacteriophage Lambda head protein D," *Gene*, 224(1-2): 45-52 (1998).

LI, et al., "Transduction of human catalase mediated by a HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells," *Free Radical Biology & Medicine*, 31(11): 1509-19 (2001).

STERNBERG and HOESS, "Display of peptides and proteins on the surface of bacteriophage λ ," *Proc. Natl. Acad. Sci. U S A.*, 92(5): 1609-13 (1995).

TOBOREK, et al., "HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium," *J. Neurochem.*, 84(1): 169-79 (2003).

TSENG, et al., "Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study," *Mol. Pharmacology*, 62(4): 864-72 (2002).

VASQUEZ and JOHNSON, "Green fluorescent protein as a reporter of adenovirus-mediated gene transfer and expression in the hypothalamic-neurohypophyseal system," *Methods Mol. Biol.*, 183: 321-9 (2002).

VIVÈS, et al., "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," *J. Biol. Chem.*, 272(25):16010-7 (1997).

WHEELER, et al., "Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain," *Biochem. Biophys. Res. Commun.*, 301(1):54-9 (2003).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Charles Vorndran /

Charles Vorndran, Ph.D., J.D.
Reg. No. 45,315

Dated: March 17, 2010

PABST PATENT GROUP LLP
1545 Peachtree Street NE
Suite 320
Atlanta, GA 30309
(404) 879-2153 (Telephone)
(404) 879-2160 (Fax)